Doximity Q1: Solid Revenue, Raised Guide, but AI Monetization Still Absent

What happened

Doximity reported fiscal Q1 2027 revenue of $157 million, up 7% year-over-year, and raised full-year guidance, signaling improving pharma demand and AI engagement. However, adjusted EBITDA fell 6% to $74.8 million with margin compressing to 47.7% as AI investment costs accelerated. The company’s Clinical AI Suite reached 150 health system purchases, but management has yet to disclose any AI-specific revenue or paid-seat metrics, leaving monetization unproven. The core Marketing Solutions business remains exposed to pharma budget caution and concentration risk from a single large customer. A strong balance sheet with $688 million in cash and ongoing buybacks provides downside cushion, but the stock needs clearer AI revenue evidence to re-rate higher.

Implication

Investors should focus on upcoming Q2 results to see if the higher guidance is sustainable and if EBITDA margins stabilize above 48%. The key catalyst is filing-level disclosure of AI revenue or paid deployments; without it, the AI narrative remains speculative. The pharma ad business, while stabilizing, still faces policy uncertainty and concentration risk that could delay recovery. The balance sheet and buybacks support valuation at current levels, but meaningful upside requires evidence of AI converting adoption into dollars. We maintain a WAIT rating until the company provides clearer monetization metrics or the stock pulls back to our attractive entry near $18.

Thesis delta

Doximity’s Q1 print marginally de-risks the FY27 revenue outlook but adds no new evidence on AI monetization. The thesis remains WAIT: the stock is fairly valued pending clearer AI revenue disclosure or a pullback to entry.